Abstract: The present invention relates to a compound of formula (I) for use in the treatment or prevention of arthritis.

Abstract: A method for representing a second presentation of audio channels or objects as a data stream, the method comprising the steps of: (a) providing a set of base signals, the base signals representing a first presentation of the audio channels or objects; (b) providing a set of transformation parameters, the transformation parameters intended to transform the first presentation into the second presentation; the transformation parameters further being specified for at least two frequency bands and including a set of multi-tap convolution matrix parameters for at least one of the frequency bands.

Abstract: The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

Abstract: A diagnostic cassette includes a substrate, to physically and electrically connect the product to a computing device, a reservoir defined within the substrate to receive a fluid sample for processing by the diagnostic cassette, a reagent to react with the fluid sample deposited in the reservoir to form a solution to enable processing of the fluid sample by the diagnostic cassette, a channel to direct the solution, and a sensor to measure a number of parameters of the solution passing through the channel. A method for measuring microfluidic samples includes receiving, in a reservoir, a fluid sample to be measured, combining the fluid sample with a reagent to create a solution, moving the solution through a channel, and measuring the solution, using sensors, as the solution passes through the channel.

Abstract: Methods and apparatuses for using a structure as a sensor are disclosed. An apparatus in accordance with an aspect of the present disclosure comprises an additively-manufactured component comprising a channel, a sensor including an connection point, wherein the sensor is arranged in the channel, and an adhesive arranged in the channel, the adhesive coupling the additively-manufactured component to the sensor, such that the connection point is accessible external to the adhesive, the sensor being configured to provide a signal at the connection point, wherein the signal provides information of an applied force on the additively-manufactured component.

Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

Abstract: A method for generating mastered audio content, the method comprising obtaining an input audio content comprising a number, M1, of audio signals, obtaining rendered presentation of the input audio content, the rendered presentation comprising a number, M2, of audio signals, obtaining a mastered presentation generated by mastering the rendered presentation, comparing the mastered presentation with the rendered presentation to determine one or more indications of differences between the mastered presentation and the rendered presentation, modifying one or more of the audio signals of the input audio content based on the indications of differences to generate the mastered audio content. With this approach, conventional, typically stereo, channel-based mastering tools can be used to provide a mastered version of any input audio content, including object-based immersive audio content.

Abstract: The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

Abstract: A buffer block apparatus for securing a node may be described. The buffer block apparatus may include a first surface having disposed thereon at least one first zero-point feature configured for a first zero-point interface with a robotic assembly apparatus; and a second surface, different from the first surface, configured to connect with a first surface of a node and form a first rigid connection between the buffer block apparatus and the node, wherein the buffer block apparatus provides at least one reference coordinate system with respect to the node.

Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

Abstract: A method for representing a second presentation of audio channels or objects as a data stream, the method comprising the steps of: (a) providing a set of base signals, the base signals representing a first presentation of the audio channels or objects; (b) providing a set of transformation parameters, the transformation parameters intended to transform the first presentation into the second presentation; the transformation parameters further being specified for at least two frequency bands and including a set of multi-tap convolution matrix parameters for at least one of the frequency bands.

Abstract: Techniques for joining nodes and subcomponents are presented herein. An apparatus in accordance with an aspect of the present disclosure comprises a 3-D printed first part having an interconnect co-printed with the first part such that the interconnect of the first part can float within the first part, and a 3-D printed second part having an interconnect co-printed with the second part such that the interconnect of the second part can float within the second part, wherein the interconnects of the first and second parts are configured to form a connection between the first and second parts.

Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which they are attached may form a 3- to 12-membered optionally substituted cyclic group; and R2 is a cyclic group substituted at the position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

Abstract: The present invention relates to a binding site of the NLRP3 inflammasome. The present invention further relates to a method of and a compound for use in inhibiting NLRP3 activation and treating a disease, disorder or condition responsive to NLRP3 inhibition. The present invention further relates to a method of reducing cellular or mitochondrial Reactive Oxygen Species (ROS) by inhibiting NLRP3 activation. The present invention further relates to a method of screening a compound to determine the extent of binding of the compound to the binding site of the NLRP3 inflammasome, and to a compound identified by such a screening method.

Abstract: Apparatus and methods for mitigating transverse mode instabilities (TMI) in high power fiber amplifiers that does not depend on active feedback loops. The apparatus and method involve the modulation of the amplitude and/or phase of selected spatial mode components of an input signal beam to increase the TMI threshold of the amplifier. Once the desired modal adjustments are made, the beam is input to a mode multiplexer whereupon an optimized output beam can be input to the active fiber of the amplifier system. By increasing the TMI threshold of the amplifier, the amplifier can be operated at higher power before TMI sets in. A control stage of the fiber amplifier system includes (a) a (seed) beam splitting section; (b) an amplitude and phase control component; and (c) a mode multiplexer that maps multiple individual signal beams to different fiber modes.

Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

Abstract: There is provided a range of novel compounds. These novel compounds may demonstrate abroad spectrum antibacterial and antifungal activity. These compounds may be active against the emerging polymyxin resistant bacteria. These compounds may also be useful when used in conjunction with other pharmaceutically active agents.